Mydecine Innovations Group Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.103
- Today's High:
- $0.15
- Open Price:
- $0.103
- 52W Low:
- $0.085
- 52W High:
- $0.656
- Prev. Close:
- $0.159
- Volume:
- 1300
Company Statistics
- Market Cap.:
- $4.22 million
- Book Value:
- -0.343
- Revenue TTM:
- $7493
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $7493
- Profit Margin:
- 0%
- Return on Assets TTM:
- -255.66%
- Return on Equity TTM:
- -1224.4%
Company Profile
Mydecine Innovations Group Inc had its IPO on under the ticker symbol MYCOF.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Mydecine Innovations Group Inc has a staff strength of 3 employees.
Stock update
Shares of Mydecine Innovations Group Inc opened at $0.1 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.1 - $0.15, and closed at $0.15.
This is a -5.66% slip from the previous day's closing price.
A total volume of 1,300 shares were traded at the close of the day’s session.
In the last one week, shares of Mydecine Innovations Group Inc have increased by +32.74%.
Mydecine Innovations Group Inc's Key Ratios
Mydecine Innovations Group Inc has a market cap of $4.22 million, indicating a price to book ratio of 23.4066 and a price to sales ratio of 677.586.
In the last 12-months Mydecine Innovations Group Inc’s revenue was $7493 with a gross profit of $7493 and an EBITDA of $-14762551. The EBITDA ratio measures Mydecine Innovations Group Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Mydecine Innovations Group Inc’s operating margin was 0% while its return on assets stood at -255.66% with a return of equity of -1224.4%.
In Q2, Mydecine Innovations Group Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 99.6%.
Mydecine Innovations Group Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.31 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Mydecine Innovations Group Inc’s profitability.
Mydecine Innovations Group Inc stock is trading at a EV to sales ratio of 1153.191 and a EV to EBITDA ratio of -0.3982. Its price to sales ratio in the trailing 12-months stood at 677.586.
Mydecine Innovations Group Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.03 million
- Total Liabilities
- $4.94 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Mydecine Innovations Group Inc ended 2024 with $1.03 million in total assets and $0 in total liabilities. Its intangible assets were valued at $1.03 million while shareholder equity stood at $-9084742.00.
Mydecine Innovations Group Inc ended 2024 with $0 in deferred long-term liabilities, $4.94 million in other current liabilities, in common stock, $-147317287.00 in retained earnings and $0 in goodwill. Its cash balance stood at $40458.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $5.17 million.
Mydecine Innovations Group Inc’s total current assets stands at $563872.00 while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $0 compared to accounts payable of $3.42 million and inventory worth $0.
In 2024, Mydecine Innovations Group Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Mydecine Innovations Group Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.15
- 52-Week High
- $0.656
- 52-Week Low
- $0.085
- Analyst Target Price
- $
Mydecine Innovations Group Inc stock is currently trading at $0.15 per share. It touched a 52-week high of $0.656 and a 52-week low of $0.656. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.13 and 200-day moving average was $0.31 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 428.4% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Mydecine Innovations Group Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Mydecine Innovations Group Inc., a biotechnology company, engages in the development and commercialization of psilocybin products for treating mental health problems. The company primarily focuses on treating smoking cessation. Its lead product drug candidates include MYCO-001, MYCO-002, MYCO003, and MYCO-004. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.